Multiple Myeloma Coverage From Every Angle
Advertisement
Advertisement

Recent News

FDA Grants Priority Review to Ruxolitinib for Acute Graft-Versus-Host-Disease
ASTRO 2018: Impact of Dosage on Re-irradiation Rates in Multiple Myeloma
FDA Approves Immunotherapy Combination in Relapsed or Refractory Multiple Myeloma
Rare Case of CML After Stem Cell Transplantation in Patient With Multiple Myeloma
Phase I Study of New Triplet Therapy for Resistant Myeloma
FDA Offers Draft Guidance on Use of MRD in Hematologic Malignancies
Investigational Therapy for Myeloma, STRO-001, Granted Orphan Drug Designation by FDA
ESMO 2018: Strategy for Offsetting Lenalidomide-Induced Rash in Multiple Myeloma
FDA Grants Priority Review to Selinexor for Pentarefractory Multiple Myeloma
Can Simple Blood Tests Diagnose Early Multiple Myeloma?
FDA Permits Use of Next-Generation Sequencing–Based Test in Multiple Myeloma
Quality Care Symposium: Steady Improvement in Survival in Multiple Myeloma
FDA Approves Once-Weekly Carfilzomib With Dexamethasone in Resistant Multiple Myeloma
Novel Approach to Restoring Beneficial Gut Bacteria After HCT
Can Artificial Intelligence Platform Optimize Combination Therapy for Multiple Myeloma?
High-Risk Subset of Newly Diagnosed Multiple Myeloma Identified
Is Resilience a Protective Factor in Disease Trajectory of Multiple Myeloma?
Former MLB Sluggers Team up to Create Awareness of Multiple Myeloma
Monoclonal Antibodies in Multiple Myeloma: Focus on Infusion-Related Reactions
ALL After Multiple Myeloma: Clonally Related or Not?
FDA Accepts Supplemental Biologics License Application for Triplet Myeloma Therapy
Accuracy of Blood Versus Urine Assays in Diagnosis of Multiple Myeloma
Potential of bb2121 CAR T-Cell Therapy in Resistant Multiple Myeloma
UAB Leads Recruitment for Novel Clinical Trial in Multiple Myeloma
Phase III ADMYRE Trial: Plitidepsin + Dexamethasone in Resistant Myeloma
FDA Issues Warning About Long-Term Use of Azithromycin After Donor Stem Cell Transplant
Pembrolizumab in Combination Therapy for Resistant Multiple Myeloma
FDA Grants Orphan Drug Designation to Human Antibody for Treatment of Multiple Myeloma
FDA Grants Fast Track Designation to Galinpepimut-S for Treatment of Myeloma
Preliminary Safety Results of Triplet Therapy for Multiple Myeloma Reported
Stand Up To Cancer Launches Dream Team to Detect Precursor Conditions of Myeloma
Clinical Trials Testing Daratumumab With Checkpoint Inhibitors in Multiple Myeloma Halted
EHA 2018: Addition of Elotuzumab to Pomalidomide and Dexamethasone in Resistant Myeloma
FDA Takes Closer Look at Use of Pembrolizumab in Multiple Myeloma
EHA 2018: Selinexor and Bortezomib Combination in Resistant Multiple Myeloma
EHA 2018: First-in-Class Selinexor in Combination Therapy for Resistant Multiple Myeloma
ASCO 2018: Novel Drug Combination Active in Relapsed Myeloma
ASCO 2018: New Phase III Data on Ibrutinib Plus Rituximab for Waldenström’s Macroglobulinemia
ASCO 2018: Halted Study Reveals Risks of Pembrolizumab Treatment in Multiple Myeloma
ASCO 2018: Once-Weekly Carfilzomib Dosing in Relapsed/Refractory Multiple Myeloma
ASCO 2018: OPTIMISMM Trial Results of Pomalidomide Triplet in Resistant Myeloma
Cancer Vaccine Granted Orphan Drug Designation by FDA for Treatment of Multiple Myeloma
Novel Chip-Based Blood Assay for Isolation of Circulating Plasma Cells in Myeloma


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.